Lisata Therapeutics Inc (LSTA)

[Viperciara]

Carl J. Pepine, MD
Carl J. Pepine

•
PreSERVE-AMI represents the first cell-therapy trial to show a reduction in mortality with administration of CD34+ cells. A unique aspect of this trial is that the investigators used high-dose CD34+ cells. In addition, patients enrolled in this trial had among the lowest baseline ejection fractions of the cell-therapy trials. The investigators did link the CD34+ cell number with a number of the outcomes. We previously published that using mobilized CD34+ cells in patients with refractory angina markedly reduced angina frequency and had a strong trend (P=.058) toward reduction in death or MI at 1 year (Losordo DW. Circ Res. 2011;109:428-436). It seems like this study too is zeroing in on something important for the CD34+ cells in ischemic heart disease. I would like to see more trials on this. All of these data are starting to fit together as important and the PreSERVE-AMI results will rejuvenate the cell therapy field.


Carl J. Pepine, MD
Chief Medical Editor, Cardiology Today